ECCO

Cielo Announces Fiscal Q3 2024 Financial Results and Provides Update on its Progress to Fuel Renewable Change

Retrieved on: 
Thursday, March 28, 2024
ECCO, CFO, News, Expander, CMC, Public expenditure, CEBA, Carbon, Biomass, Bank statement, TCD, Biogas, Project, Economics, Renewable energy

CALGARY, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTC:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low-carbon fuel from wood by-products, today announced its financial results for the three and nine months ended January 31, 2024, along with an update on the Company’s progress as Cielo fuels renewable change.

Key Points: 
  • CALGARY, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTC:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low-carbon fuel from wood by-products, today announced its financial results for the three and nine months ended January 31, 2024, along with an update on the Company’s progress as Cielo fuels renewable change.
  • All financial information in this news release is reported in Canadian dollars, unless otherwise indicated.
  • "We believe the closing of the asset purchase transaction with Expander Energy during Q3 2024 represents a pivotal moment on our journey, positioning Cielo with an economically sustainable and market-ready solution.
  • Cielo has a clear line of sight to produce our net-zero carbon intensity Bio-SynDiesel®,” said Ryan Jackson, CEO of Cielo.

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Research, Ulcerative colitis, ECCO, LTE, ACG, Patient, UC, Journal, Biomarker, NEXUS, Wind, Insurance, Abstract, American College, Clinical trial, Safety, Pharmacokinetics, Poster, NLRX1, European, PLXDC2, Pharmaceutical industry

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.
  • Top-line results are planned for the fourth quarter of 2024.
  • Research and development expenses were $3.1 million for the fourth quarter of 2023, compared to $3.4 million for the fourth quarter of 2022.
  • General and administrative expenses were $3.5 million for the fourth quarter of 2023, compared to $3.1 million for the fourth quarter of 2022.

Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.

Retrieved on: 
Tuesday, March 5, 2024
CNRS, Regeneration, Crohn's disease, EIC, Exosome, Quality of life, Fistula, Stenosis, B cell, Patient, Fibrosis, Intellectual property, Congress, Research, ECCO, Pharmaceutical industry

Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.

Key Points: 
  • Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract.
  • This new worldwide license marks a significant step forward in EVerZom's mission to bring innovative exosome-based therapeutic solutions to patients suffering from serious digestive diseases.
  • Paris, March 5, 2024 - EVerZom, a CNRS/Université Paris Cité spin-off specializing in exosomes, has announced the signature of a second exclusive license agreement with Erganeo for the development of EVerGel ™, a drug candidate tailored for the healing of digestive tissues.
  • EVerZom's first clinical application focuses on digestive tissue regeneration using naive exosomes derived from stem cells encapsulated in a gel called EVerGel ™.

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

Retrieved on: 
Thursday, February 22, 2024
SAN, Ulcerative colitis, European, Inflammation, UC, Congress, ECCO, Pharmaceutical industry

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that data from the Phase 2 trial of VTX002 in ulcerative colitis will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 22, 2024, in Stockholm, Sweden.

Key Points: 
  • SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that data from the Phase 2 trial of VTX002 in ulcerative colitis will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 22, 2024, in Stockholm, Sweden.
  • “We are very excited to present the results of the VTX002 Phase 2 trial in ulcerative colitis during the 19th Congress of the European Crohn’s and Colitis Organisation,” said Raju Mohan, Chief Executive Officer.
  • “We believe these data establish VTX002 as a highly attractive oral therapy for UC based on its compelling efficacy profile, including a potentially differentiated rate of endoscopic remission and histologic-endoscopic mucosal improvement, and its potential best-in-class safety profile.”
    Presenter: Bruce E. Sands, M.D., M.S.
  • ; Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine, Mount Sinai, NY

Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress

Retrieved on: 
Friday, February 23, 2024
Health, Pharmaceutical, Celltrion, Ulcerative colitis, Week, Crohn's disease, European, Safety, UC, Abstract, Patient, IBD, Congress, ECCO

These data were presented as poster presentations at the 19th European Crohn’s and Colitis Organisation (ECCO) annual congress in Stockholm, Sweden.

Key Points: 
  • These data were presented as poster presentations at the 19th European Crohn’s and Colitis Organisation (ECCO) annual congress in Stockholm, Sweden.
  • The LIBERTY-CD and LIBERTY-UC studies were continued up to 102 weeks as extension phase treatments, building on the initial LIBERTY trials.
  • The two-year studies assessed the long-term efficacy and safety of CT-P13 SC in patients with Crohn's disease (CD) and ulcerative colitis (UC), respectively.
  • “The early observation of mucosal healing at Week 22 showcases the potential of subcutaneous infliximab treatment in improving patient care,” said Nam Lee, Medical Director at Celltrion.

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Retrieved on: 
Tuesday, February 20, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, SNY, SAN, Ulcerative colitis, Crohn's disease, TEVA, Inflammation, European, Teva, Teva Pharmaceuticals, Asthma, Gastrointestinal tract, Safety, UC, Immunoglobulin G, Inflammatory bowel disease, Patient, Fibrosis, TL1A, IBD, Medication, TNF, ECCO, Pharmaceutical industry

“These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.

Key Points: 
  • “These results from the first-in-human trials of anti-TL1A (TEV-’574) are exciting because they show that it effectively engages with the TL1A target, supports its safety profile and is well-tolerated.
  • “We are currently investigating the efficacy and safety of anti-TL1A (TEV-’574) in IBD through the RELIEVE UCCD Phase 2 trial, which features an innovative and efficient basket study design allowing the inclusion of patients with either type of IBD (ulcerative colitis and Crohn’s disease).
  • Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement, and Sanofi will lead the development of the Phase 3 program.
  • Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Crohn's disease, Inflammation, FDA, Animal, Poster, Congress, Ulcer, IND, ECCO, Cancer, Pharmaceutical industry

Crohn's disease is a chronic and difficult-to-treat autoimmune disorder.

Key Points: 
  • Crohn's disease is a chronic and difficult-to-treat autoimmune disorder.
  • The current available therapeutic options for this condition are very limited, and there remain significant unmet medical needs.
  • In preclinical studies, KPG-818 demonstrated potent therapeutic efficacy in mouse model of Crohn's disease.
  • Based on the recent Pre-IND meeting with the FDA, Kangpu Biopharmaceuticals will submit IND application for Phase II clinical trials of KPG-818 for Crohn's disease in the United States.

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

Retrieved on: 
Monday, February 19, 2024
ABBV, Ulcerative colitis, Collection, Crohn's disease, Research, Inflammatory Bowel Diseases, University of Calgary, Risankizumab, AbbVie, INSPIRE, Safety, University, UC, Boehringer Ingelheim, Burrill Bernard Crohn, Abstract, Inflammatory bowel disease, Patient, Ustekinumab, Pharming, Medicine, IBD, Disease, Congress, ECCO, Pharmaceutical industry

NORTH CHICAGO, Ill., Feb. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.

Key Points: 
  • The research spans risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn's disease (CD) and ulcerative colitis (UC).
  • "Despite continued advancements, many patients are still suffering from the debilitating effects of living with IBD," said Sofie Berg, Pharm.D, Ph.D., therapeutic area head, international immunology, International Medical Affairs, AbbVie.
  • "It is critically important that as the treatment paradigm shifts, the gastroenterology community shifts with it.
  • SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

Clarience Technologies Acquires Safe Fleet to Expand Safety Technology Portfolio, Broaden Customer Reach into new Market Segments

Retrieved on: 
Thursday, February 15, 2024
Technology, Audio, Video, Fleet Management, Automotive Manufacturing, Manufacturing, Other Transport, Automotive, Trucking, Vehicle Technology, Transport, Software, Other Automotive, Hardware, Logistics, Supply Chain Management, Acquisition, Multimedia, BMO Capital Markets, Injury, Safety, Genstar Capital, Agriculture, Recycling, UBS, Law enforcement, Weil, Gotshal & Manges, ECCO, Shipbuilding

View the full release here: https://www.businesswire.com/news/home/20240215329713/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240215329713/en/
    “Clarience Technologies and Safe Fleet share a common mission of making transportation safer and smarter through technology,” said Brian Kupchella, Chief Executive Officer of Clarience Technologies.
  • Safe Fleet is also a leading fleet video technology provider in North America, with over 1.5 million video systems deployed to date.
  • The acquisition of Safe Fleet increases Clarience Technologies’ total workforce to over 4,000 employees at nearly 50 locations worldwide.
  • With Safe Fleet, Clarience Technologies strengthens its position in several industry segments, including school transportation, transit, fire and emergency, law enforcement, waste, industrial and recreational vehicles.

Cielo Provides Update on Continued Progress and Milestones Achieved to Advance Carseland Bio-SynDiesel® Project

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, Engineering, Cielo, Wood, CMC, Expander, ECCO, Biomass, Carbon, Municipal solid waste, NEWS, Protected area, Oil

CALGARY, Alberta, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV: CMC; OTC: CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging environmental technology to produce renewable fuel from wood by-products, is pleased to share an update on its Carseland, Alberta Bio-SynDiesel® Project (the “Carseland Project”).

Key Points: 
  • CALGARY, Alberta, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV: CMC; OTC: CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging environmental technology to produce renewable fuel from wood by-products, is pleased to share an update on its Carseland, Alberta Bio-SynDiesel® Project (the “Carseland Project”).
  • Once completed, the Carseland Project represents Cielo’s first commercial by-product-to-fuels facility designed to convert wood by-products into low carbon intensity renewable Bio-SynDiesel® fuel.
  • This contract provides Cielo with an ongoing and cost-effective supply of the requisite biomass feedstock for the Carseland Project.
  • Cielo looks forward to providing continued updates as further progress is made and milestones are achieved.